Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

West Pharmaceutical Services, Inc. (WST) — XLV Health Care · S&P 500 Profile |西氏製藥服務介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

West Pharmaceutical Services, Inc. (WST) — Business, History & S&P 500 Profile |西氏製藥服務介紹

West Pharmaceutical company profile · pharma packaging & drug delivery components (vials, stoppers) · history · financial snapshot · S&P 500 rank #336 · 西氏製藥服務公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 2, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$28.46B
Nov 2, 2026 · Slickcharts (frozen benchmark)
S&P 500 WEIGHT
0.04%
Rank #336 · Nov 2, 2026 (Slickcharts)
FY2025 REVENUE
$3.07B
+6.3% YoY
FY2025 NET INCOME
$493.7M
FY2025 net income

SNAPSHOT

TickerWST (NYSE)
CompanyWest Pharmaceutical Services, Inc.
GICS sector / industryHealth Care (XLV) / Life Sciences Tools & Services
S&P 500 rank (by weight)#336 · 0.04% (Nov 2, 2026)
Sector rank (by market cap)#44 in Health Care (Nov 2, 2026)
Share price (frozen benchmark)$408.52 (Nov 2, 2026)
HeadquartersExton, Pennsylvania
Founded1923 (as The West Company)
CEOEric M. Green (President and CEO)
Employeesabout 10,800 (FY2025 year-end)
Market cap$28.46B (Nov 2, 2026)

WHAT IT DOES

West Pharmaceutical Services makes the packaging and delivery components that injectable drugs travel in — rubber stoppers, seals, glass vials and plungers, plus drug-delivery devices — selling to pharmaceutical and biotech companies worldwide.

The model is consumables plus validation: once a stopper or vial is qualified in a drug's filing, switching suppliers is costly, so volumes follow drug production. FY2025 revenue was $3,074M, up 6.3% from $2,893M, operating income was $636M, net income was $493.7M, and diluted EPS was $6.83.

One provider reports operating income of $617M on a different line basis — the $636M figure is used and the difference is flagged. The company had 25 manufacturing facilities at year-end, 26 after the 2026 Dublin expansion; the 26 figure is NOT a FY2025 figure and is not presented as one.

BUSINESS SEGMENTS — FY2025

SegmentRevenueShareYoY
Proprietary Products———
Contract-Manufactured Products———
Segment revenue split not stated in the sources used; units are listed qualitatively, with revenue, share and YoY shown as —. Do not read a split from this table.

HISTORY

YearMilestone
1923The West Company founded
2020Components in high demand as COVID-19 vaccines scale up
2025FY2025 revenue reaches $3,074M, up 6.3%, with 25 manufacturing facilities at year-end

COMPETITIVE POSITION

  • Qualification moat — components qualified in drug filings are hard to replace.
  • Biologics tailwind — injectable biologics grow faster than oral drugs.
  • Global footprint — 25 plants at year-end serve customers worldwide.
  • Customer concentration — large pharma buyers drive a large share of orders.
  • Competition — Datwyler, Aptar and Stevanato contest the same components.

FINANCIAL SNAPSHOT — FY2025

Total revenue$3,074M (+6.3% YoY)
Operating income$636M
Net income$493.7M
Diluted EPS$6.83
Source: West Pharmaceutical Services FY2025 results / Form 10-K (filed Feb 17, 2026). One provider reports operating income of $617M on a different line basis — the $636M figure is used and the difference is flagged. Facility count 26 after the 2026 Dublin expansion is not a FY2025 figure.

KEY RISKS

  • Destocking — customers drawing down vial inventories cut orders.
  • Biologics cycles — drug launch delays slow component demand.
  • Pricing — large pharma buyers press component prices.
  • Capacity — new plants must fill before they earn.
  • Quality — a defect in a qualified component can halt a drug line.

WHY IT MATTERS FOR THE S&P 500

West Pharmaceutical Services is the S&P 500's injectable-packaging name: at a 0.04% index weight and #44 in Health Care by market cap, it is the index's main exposure to drug-delivery components.

Its volumes are a standing read on biologics production — vial and stopper orders move before drug sales do.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Nov 2, 2026 close) and Slickcharts S&P 500 analysis page (market cap)
FinancialsWest Pharmaceutical Services FY2025 results / Form 10-K, filed Feb 17, 2026 (fiscal year ended Dec 31, 2025), company profile sources
Sector classificationGICS (Life Sciences Tools & Services) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

WST

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼WST(NYSE)
公司West Pharmaceutical Services, Inc.
GICS 板塊/行業醫療保健(XLV)/生命科學工具與服務
標普500排名(按權重)#336 · 0.04%(2026 年 11 月 2 日)
板塊內排名(按市值)醫療保健第 #44(2026 年 11 月 2 日)
股價(凍結基準)$408.52(2026 年 11 月 2 日)
總部美國賓夕法尼亞州埃克斯頓
成立1923 年(前身為 The West Company)
行政總裁Eric M. Green(總裁兼行政總裁)
員工約 10,800(FY2025 年末)
市值$28.46B(2026 年 11 月 2 日)

業務概覽

西氏製藥服務製造注射藥物所用的包裝與輸送零件——橡膠塞、密封件、玻璃瓶與推桿,以及給藥裝置——向全球製藥與生物科技公司銷售。

其模式為耗材加驗證:一旦塞子或藥瓶獲納入藥物申請,轉換供應商成本高昂,故銷量跟隨藥物生產。FY2025 收入為 $3,074M,同比增長 6.3%(FY2024 為 $2,893M),營業利潤為 $636M,淨利潤為 $493.7M,攤薄每股收益為 $6.83。

一家來源按不同口徑報營業利潤 $617M——此處用 $636M,差異已標示。公司年末有 25 間製造廠,2026 年都柏林擴建後為 26 間;26 間並非 FY2025 數字,不作 FY2025 數字列示。

業務板塊 — FY2025

板塊收入佔比同比
專有產品———
合約製造產品———
板塊收入拆分未見於所用來源;本表只作定性列示,收入、佔比與同比均記為 —,請勿據此推斷拆分。

歷史沿革

年份里程碑
1923The West Company 創立
2020新冠疫苗量產令零件需求大增
2025FY2025 收入達 $3,074M,同比增長 6.3%,年末有 25 間製造廠

競爭地位

  • 驗證護城河——獲納入藥物申請的零件難以取代。
  • 生物製劑順風——注射生物製劑增長快於口服藥。
  • 全球佈局——年末 25 間工廠服務全球客戶。
  • 客戶集中——大型製藥買家推動大部分訂單。
  • 競爭——Datwyler、Aptar 與 Stevanato 爭奪同一批零件。

財務快照 — FY2025

總收入$3,074M(同比 +6.3%)
營業利潤$636M
淨利潤$493.7M
攤薄每股收益$6.83
來源:西氏製藥服務 FY2025 業績/Form 10-K(2026 年 2 月 17 日提交)。一家來源按不同口徑報營業利潤 $617M——此處用 $636M,差異已標示。2026 年都柏林擴建後的 26 間工廠並非 FY2025 數字。

主要風險

  • 去庫存——客戶消耗藥瓶庫存令訂單減少。
  • 生物製劑週期——藥物上市延遲放緩零件需求。
  • 定價——大型製藥買家壓低零件價格。
  • 產能——新廠必須填滿才有盈利。
  • 質量——合格零件缺陷可令藥物生產線停頓。

對標普500的重要性

西氏製藥服務是標普500的注射包裝標的:指數權重 0.04%、醫療保健板塊市值第 #44,是指數對給藥零件的主要敞口。

其銷量,是生物製劑生產的常設讀數——藥瓶與塞子訂單往往先於藥物銷售變動。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 2 日收盤)及 Slickcharts 標普500分析頁(市值)
財務西氏製藥服務 FY2025 業績/Form 10-K,2026 年 2 月 17 日提交(財政年度截至 2025 年 12 月 31 日)、公司簡介來源
板塊分類GICS(生命科學工具與服務),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

WST

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · WST
Data as of Nov 2, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · CenterPoint Energy, Inc. (CNP) — XLU Utilities · S&P 500 Profile |中點能源介紹Next · DTE Energy Company (DTE) — XLU Utilities · S&P 500 Profile |DTE能源介紹

Entered 2026-11-03 13:13 · updated 2026-11-15 00:18 · rev 5